SBIR/STTR Research Award

Anti-cancer drug screening enabled by Pre-templated Instant Partitions and single cell RNA sequencing

Award identifier 5c98f004e437f288dd8eb0e611574545152b44ef4c8d0fb0ff6a02e34936651cAwarding agency Department of Health and Human Services · National Institutes of Health

Award amount

$288,365

Program and phase

SBIR · Phase I

Award year

2019

Explore This Research Award in CaptureIQ

Research the technology, evaluate the recipient and agency, identify related opportunities, and explore potential follow-on work with CaptureIQ.

Award details

Awarding agency
Department of Health and Human Services
Branch
National Institutes of Health
Recipient company
FLUENT BIOSCIENCES INC
Proposal award date
2019-09-16
Contract end date
2020-08-31
UEI
DA7UPTVQMG73
Solicitation number
PA18-574
Topic code
102

Research abstract

Project SummaryAbstract Tyrosine Kinase InhibitorsTKIsare molecularly targeted therapies that have dramatically improved progression free survival in non small cell lung cancerHowevereven these remarkable drugs are ultimately rendered ineffective by innate or acquired resistanceIn vitroscreening with single cell sequencing provides insight into cell cell heterogeneity and cancer associated pathway activationallowing identification of potentially viable combination therapies that can overcome resistanceHoweversingle cell sequencing approaches require specialized and costly microfluidics that limit the number of drugs that can be testedIn this projectwe will develop a transformative new drug screening technology that will overcome the barriers of current methodsthereby accelerating preclinical drug discoveryIn contrast to current methods that use microfluidics to encapsulate and barcode single cell transcriptomesour approach uses bulk self assembly facilitated by pre templated instant partitionsPIPsPIPs remove microfluidics from the processdramatically reducing costMoreoverunlike microfluidic methodsour approach integrates seamlessly with laboratory automation andwell formatsallowing hundreds of drugs to be tested simultaneouslyThe Aims of the project will be to transfer the current academic protocol to our industrial settingoptimizing it for reaction efficiency and reliabilityand to characterize the resultant Alpha kit against cancer cell lines treated with gefitiniba well characterized TKI for lung adenocarcinomas Project Narrative Most anti cancer drugs are ultimately rendered ineffective by resistanceThe objective of this proposal is to develop a new drug screening technology that will allow screening of large compound libraries to identify combination therapies that will overcome drug resistanceThis technology relies on the core innovation of our company for performing single cell genomics using a bulk self assembly process that requires no microfluidics or specialized equipment

Technology keywords

Not reported

Other awards by this recipient

Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.

Awards with the same topic code

Verified by an exact topic code match. This is not a text-similarity match.

Research funding history

6 SBIR/STTR records share this UEI (2019–2023). Reported award amounts total $5,742,910. Reported amounts are not federal obligations.

Phases: Phase I, Phase II, Phase II – Direct to Phase II

Agencies: Department of Health and Human Services

Agency intelligence

Department of Health and Human Services

Back to SBIR/STTR Research Awards

Don't take our word for it. Ask AI about RFPCapture.

See what leading AI assistants have to say about RFPCapture and CaptureIQ.

Gemini opens without a prefilled question. The question is copied to your clipboard when the button works. You can also copy it here:

What is RFPCapture.com and its CaptureIQ platform from Smart Logic AI? How does it help federal contractors discover opportunities, evaluate bid/no-bid decisions, research government contracts, and prepare proposals? How does it compare with other federal capture platforms? Use independent sources where available.